PubMed Health⌕ Search

Biomedical subjects

Kyu Jin Oh

Publications and source records attributed to Kyu Jin Oh.

5 recordsLinked to original sources
PubMed2006

Unstable angina complicated by vasospasm and intracoronary thrombus and no evidence of plaque rupture.

A 57-year-old man came to the emergency room because of abrupt chest pain for 30min. ST elevations in inferior lead were normalized following sublingual nitroglycerin. He performed an exercise test on Bruce protocol and exercised up to 12min (13 METs) without chest pain and ST-T changes on the next day. We performed coronary angiography to rule out coronary vasospasm; however, we did not perform provocation test due to thombus in the culprit lesion. After medical treatment for 6days, follow-up coronary angiogram revealed no thrombus in the previous site and intravascular ultrasound did not demonstrate plaque rupture. We concluded that prolonged spasm might cause prolonged coronary flow limitation and induce acute thrombus formation without plaque rupture. This finding may be an important pathogenesis of acute coronary syndrome in patients with variant angina.

Angina, Unstable↗
PubMed2006

The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: randomized controlled prospective study.

BACKGROUND: Previous studies with dexamethasone-eluting stents could not elucidate the role of dexamethasone in the prevention of neointimal hyperplasia because they did not compare their results with a control group. We prospectively evaluated the clinical and angiographic outcomes of dexamethasone-eluting stents, comparing them with unloaded stents of an identical design. METHODS: A total of 92 patients (98 lesions) were randomly assigned to the dexamethasone group (67 patients, 71 lesions) or control group (25 patients, 27 lesions). The inclusion criteria for a stent implantation were a de novo lesion with a diameter of 2.60 to 4.0 mm. BiodivYsio Drug Delivery phosphorylcholine-coated stents (Biocompatibles Ltd, Galway, Ireland) were immersed in a 20-mg/mL dexamethasone solution, yielding a total dexamethasone dose of 0.5 microg/mm2 per stent. RESULTS: The total major adverse cardiac events rate at 12 months was significantly lower in the dexamethasone group, as compared with the control group (10.4% [7/67] vs 28.0% [7/25], P = .037). The binary restenosis rate at 6 months was 11.9% (7/59) in the dexamethasone group and 42.9% (9/21) in the control group (P = .002). The use of dexamethasone-eluting stents was the only independent predictor for the major adverse cardiac event at 12 months (relative risk 0.20, 95% CI 0.06-0.68, P = .009) and binary restenosis at 6 months (relative risk 0.17, 95% CI 0.05-0.60, P = .006) by multivariate analysis. CONCLUSIONS: Dexamethasone-eluting stents exhibited an improvement in the clinical and angiographic outcomes, as compared with the control stents. These results suggest that dexamethasone may play an important role in the inhibition of the polymer-induced inflammation in the era of drug-eluting stents.

Aged↗
PubMed2005

Diffuse three-vessel coronary artery spasm.

A 50-year-old woman came to the hospital because of chest pain, mostly occurring in the early morning at rest. She performed an exercise test on Bruce protocol and exercised up to 11 min (13 METs) without chest pain. Following ergonovine provocation test, diffuse three-vessel coronary artery spasm was identified.

Coronary Angiography↗